Zomepirac
Systematic (IUPAC) name | |
---|---|
2-[5-(4-chlorobenzoyl)-1,4-dimethyl-pyrrol-2-yl]acetic acid
|
|
Clinical data | |
Legal status |
|
Routes of administration |
oral |
Identifiers | |
CAS Number | 33369-31-2 |
ATC code | M01AB04 (WHO) |
PubChem | CID: 5733 |
DrugBank | DB04828 |
ChemSpider | 5531 |
UNII | 822G987U9J |
ChEBI | CHEBI:35859 |
ChEMBL | CHEMBL19490 |
Chemical data | |
Formula | C15H14ClNO3 |
Molecular mass | 291.729 g/mol |
|
|
|
|
(what is this?) (verify) |
Zomepirac is an orally effective NSAID that has antipyretic actions. It was developed by McNeil Pharmaceutical and approved by the FDA in 1980 and sold as the sodium salt, zomepirac sodium, under the brand name Zomax. Due to its clinical effectiveness, it was preferred by doctors in many situations and obtained a large share of the analgesics market; however, it was subsequently withdrawn in March 1983 due to its tendency to cause serious anaphylaxis in an unpredictable subset of the patient population.[1][2]
Contents
Indications
Zomepirac was indicated for the management of mild to severe pain.[3] Multiple clinical trials demonstrated zomepirac to be more effective than aspirin or codeine alone and to be as effective as analgesic combinations containing codeine or other opioids.[4][5][6][7][8][9][10] Zomepirac provided analgesia comparable with usual intramuscular doses of morphine in postoperative pain and that with long-term use, neither tolerance to its analgesic effect nor psychological or physical dependence had been demonstrated.[3][11]
Chemical structure
Zomepirac is the sodium salt of 5-(4-chlorobenzoyl)-1,4 dimethyl-1H-pyrrole-2-acetate dihydrate. It is a pyrrole-acetic acid which is structurally related to tolmetin.
Mechanism of action
It is a prostaglandin synthetase inhibitor.[12]
Toxicity
Zomepirac does not cause anaphylaxis directly, but it is metabolised by UGT to a reactive glucuronide, which binds irreversibly to plasma albumin.[13]
Synthesis
A NSAID in which the benzene ring carrying the acetic acid moiety has been replaced by a pyrrole grouping is zomepirac.
It is synthesized from Diethyl 1,3-acetonedicarboxylate, chloroacetone, and aqueous MeNH2 via modification of the Hantzsch pyrrole synthesis to give intermediate 1. Saponification, monoesterification, and thermal decarboxylation gives ester 2. This is acylated with N,N-dimethyl-p-chlorobenzamide, and finally saponification gives zomepirac (3).
References
- ↑ Peter H. Rheinstein, Reporting of adverse drug events: a key to postmarketing drug safety, American Family Physician, Sept, 1992
- ↑ Mark P. Grillo and Fengmei Hua, IDENTIFICATION OF ZOMEPIRAC-S-ACYL-GLUTATHIONE IN VITRO IN INCUBATIONS WITH RAT HEPATOCYTES AND IN VIVO IN RAT BILE, Drug Metabolism and Disposition, August 19, 2003
- ↑ 3.0 3.1 Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ DC McLeod, Zomepirac (Zomax, McNeil Pharmaceutical), Drug Intelligence & Clinical Pharmacy: Vol. 15, No. 7, pp. 522-530.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ J. R. Carson, DE 2102746; idem, US 3752826 (1971, 1973 both to McNeil).